We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Angiopoietin-Like 2 Is a Biomarker for Diabetic Foot Patients

By LabMedica International staff writers
Posted on 14 Jan 2021
Print article
Image: Human Total Angiopoietin ELISA assay (Photo courtesy of Immuno-biological laboratories Co).
Image: Human Total Angiopoietin ELISA assay (Photo courtesy of Immuno-biological laboratories Co).
Diabetic foot ulcers (DFUs) are one of the common complications in type 2 diabetes mellitus
patients and are chartered by lower extremity vascular obstructions, persistent foot infections, ulcers, and deep tissue destruction.

Circulating angiopoietin-like 2 (ANGPTL2) protein levels are known to be significantly increased in numerous chronic inflammatory diseases and are associated with the diagnosis and/or prognosis of cardiovascular diseases, diabetes, chronic kidney disease, and various types of cancers.

Endocrinologists at Beijing Luhe Hospital (Beijing, China) recruited a total of 68 participants with type 2 diabetes mellitus (T2DM) including 28 patients with DFU and 40 diabetic patients without DFUs. The diagnosis of T2DM was based on the 1999 World Health Organization Criteria, which fulfills random blood glucose ≥11.1 mmol/L and/or fasting blood glucose (FBG) ≥ 7.0 mmol/L and/or 2 hour blood glucose, during an oral glucose tolerance test (OGTT) ≥ 11.1 mmol/L.

Routine laboratory measurements were performed, including fasting plasma glucose (FBG, mmol/L), alanine transaminase (ALT,U/L), aspartate transaminase (AST,U/L), glutamyl transpeptidase (γ-GT,U/L), triglyceride (TG, mmol/L), total cholesterol (CHO, mmol/L), low density lipoprotein cholesterol (LDL-C, mmol/L), high density lipoprotein cholesterol (HDL-C, mmol/L), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and white blood cell count (WBC). Serum ANGPTL2 was measured by using a commercially available human ELISA kits (Immuno-biological laboratories Co., Ltd., Fujioka-Shi, Japan) and Vascular endothelial growth factor (VEGF) (R&D Systems, Minneapolis, MN, USA).

The scientists reported that serum levels of ANGPTL2 were significantly higher in patients with DFUs than those in diabetic control ((T2DM versus DFU: 4.221 ± 1.301 versus 6.561 ± 2.335 μg/L). Serum ANGPTL2 levels were higher in the advanced stages of DFUs. Spearman correlation analysis revealed strong positive associations of ANGPTL2 with CRP, VEGF and ESR in all subjects. In addition, serum ANGPTL2 was still positively correlated with DFUs stage after adjusting the risk factors. After adjusting for age, sex, HbA1c and duration of diabetes, ANGPTL2 was found to be independently associated with the presence of DFUs.

The authors concluded that circulating ANGPTL2 levels are an independent risk factor for DFUs and are closely related to the severity of diabetic foot. ANGPTL2 may play important roles in the development of DFUs. The study was originally published on November 30, 2020 in the journal BMC Endocrine Disorders.

Related Links:
Beijing Luhe Hospital
Immuno-biological laboratories Co., Ltd
R&D Systems


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.